𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CD3×CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin’s lymphoma

✍ Scribed by Oliver Manzke; Sandra Titzer; Hans Tesch; Volker Diehl; H. Bohlen

Book ID
105968255
Publisher
Springer-Verlag
Year
1997
Tongue
English
Weight
223 KB
Volume
45
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Locoregional treatment of low-grade B-ce
Locoregional treatment of low-grade B-cell lymphoma with CD3×CD19 bispecific antibodies and CD28 costimulation: I. Clinical phase I evaluation
✍ Oliver Manzke; Hans Tesch; Peter Borchmann; Jürgen Wolf; Klaus Lackner; Axel Gos 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 240 KB

We describe the first clinical application of T-cell-recruiting bispecific antibodies directly into the tumor without the need to preactivate the effector cells. In a Phase I clinical trial, 10 patients with low-grade B-cell lymphoma were treated by a single locoregional injection of CD3؋CD19 bispec

Effect of tetravalent bispecific CD19×CD
Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells
✍ Uwe Reusch; Fabrice Le Gall; Manfred Hensel; Gerhard Moldenhauer; Anthony D. Ho; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 284 KB

## Abstract To develop an effective antitumor immunotherapy for B‐lineage non‐Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B‐cell marker) and CD3 (T‐cell antigen). Here, we report the effective killing of malignant primary B cells from patien